4-氯-6-氮杂吲哚 | 1188313-15-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4-氯-6-氮杂吲哚
• 中文别名: 4-氯-1H-吡咯并[2,3-c]吡啶；4-氯-1H-吡咯并[2,3-C]吡啶
• 英文名称: 4-chloro-1H-pyrrolo[2,3-c]pyridine
• CAS: 1188313-15-6
• 化学式: C₇H₅ClN₂
• 分子量: 152.583
• InChiKey: UMYWTYDKYPYCGX-UHFFFAOYSA-N

物化性质

• 沸点：
  316.1±22.0 °C(Predicted)
• 密度：
  1.425

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氯-6-氮杂吲哚 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 氢气 、 三乙胺 、 锌 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 二甲胺 为溶剂， 140.0 ℃ 、344.75 kPa 条件下， 反应 25.75h， 生成 4-cyano-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators

  摘要：

  We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.

  DOI：

  10.1021/jm401625b

文献信息

• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET PROCÉDÉS
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011149827A1

  公开（公告）日：2011-12-01

  Disclosed are compounds having the Formula (I), wherein X, Y, Z, R1, R2 and R3 are as defined herein, and methods of making and using the same.

  揭示了具有化学式（I）的化合物，其中X、Y、Z、R1、R2和R3如本文所定义，并公开了制备和使用这些化合物的方法。
• [EN] 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 2,4-DIAMINOPYRIMIDINE EN TANT QU'INHIBITEURS DE LA SÉRINE/THRÉONINE KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013092940A1

  公开（公告）日：2013-06-27

  Compounds having the formula I wherein A, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

  具有以下公式I的化合物，其中A、R1a、R1b、R2、R3、R4、R5、R6、R7、R8、Ra、Rb、X1、X2、X3和n的定义如本文所述，是PAK1的抑制剂。还披露了用于治疗癌症和增生性疾病的组合物和方法。
• NOVEL P2X7R ANTAGONISTS AND THEIR USE
  申请人：Bös Michael

  公开号：US20090312366A1

  公开（公告）日：2009-12-17

  The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.

  本申请涉及新型P2X7R拮抗剂，其为吲哚-3-羧酰胺或氮杂吲哚-3-羧酰胺化合物，包括这些化合物的药物组合物，以及它们用于预防或治疗由P2X7R活性介导的疾病。
• [EN] METHOD OF TREATMENT OF TRANSPLANT REJECTION<br/>[FR] METHODE POUR TRAITER LE REJET DE GREFFE
  申请人：PFIZER PROD INC

  公开号：WO2005060972A2

  公开（公告）日：2005-07-07

  A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula (I) wherein R1, R2 and R3 are as defined above.

  一种治疗或预防慢性器官移植排斥的方法，包括给予式(I)中R1、R2和R3如上定义的化合物。
• SERINE/THREONINE KINASE INHIBITORS
  申请人：Genentech, Inc.

  公开号：US20130178486A1

  公开（公告）日：2013-07-11

  Compounds having the formula I wherein A, R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R a , R b , X 1 , X 2 , X 3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

  具有以下式子I的化合物，其中A，R1a，R1b，R2，R3，R4，R5，R6，R7，R8，Ra，Rb，X1，X2，X3和n的定义如本文所述，是PAK1的抑制剂。还公开了用于治疗癌症和增殖性疾病的组合物和方法。